Uncategorized

FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm

Published

on

The FDA’s rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version